.png){kind=icon}
.png){kind=icon}
Return
Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer
.png){kind=icon}
OA
AI
DOI：10.1093/narcan/zcad045.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, efficacy is limited by progression to castration-resistant PC (CRPC), usually due to AR re-activation via mechanisms that include AR amplification and structural rearrangement. These two classes of AR alterations often co-occur in CRPC tumors, but it is unclear whether this reflects intercellular or intracellular heterogeneity of AR. Resolving this is important for developing new therapies and predictive biomarkers. Here, we analyzed 41 CRPC tumors and 6 patient-derived xenografts (PDXs) using linked-read DNA-sequencing, and identified 7 tumors that developed complex, multiply-rearranged AR gene structures in conjunction with very high AR copy number. Analysis of PDX models by optical genome mapping and fluorescence in situ hybridization showed that AR residing on extrachromosomal DNA (ecDNA) was an underlying mechanism, and was associated with elevated levels and diversity of AR expression. This study identifies co-evolution of AR gene copy number and structural complexity via ecDNA as a mechanism associated with endocrine therapy resistance. [GRAPHICS] .
Keywords:
ANDROGEN-RECEPTOR
ENZALUTAMIDE
ABIRATERONE
HETEROGENEITY
EVOLUTION
SURVIVAL
MODELS
AR-V7
DNA
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
N
IF:
3.2
Papers:
330
Citations:
807
View more organizations